Dr. Slamon describes results of genomic seqncng to determine who benefits from adding

[Lani]

everolimus (an mTor inhibitor which ffeecets the PI3k pathway) to herceptin in Stage IV patients

http://meetinglibrary.asco.org/content/112020?media=vm

[sarah]

yes interesting and here's more on the subject:
http://www.ascopost.com/ViewNews.aspx?nid=20674
sarah